(Alliance News) - Stock prices in London were mixed at midday on Tuesday, as the FTSE 100 hit a new record but the FTSE 250 index underperformed. The FTSE 100 index was up 14.40 points, 0.2%, at 9,668 ...

Evoke also reiterated its medium-term financial targets of 5% to 9% annual revenue growth, around 100 basis points of adjusted Ebitda margin expansion per year, and leverage below 3.5 times by the end ...

RWS noted that revenue on an organic constant currency basis was "broadly in line" with the prior year's GBP718.2 million, however, on a reported basis, revenue is expected to fall by around 3.9% to ...

Still, Yellow Cake noted that the spot price showed "notable volatility" in the three months, falling 9% on a monthly basis to USD71.10/lb at the end of July before increasing to USD82.00 at September ...

On-year economic growth slowed to 10.5% in the third quarter from 17.1% in the second quarter. Separately, the CSO announced that the volume of retail sales rose by 0.2% monthly in September and 3.5% ...

Looking ahead to financial 2026, Auction Technology said expects its performance to be in line with current market expectations, which it placed at revenue of USD241.3 million and adjusted Ebitda of ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Winvia expects a market capitalisation of GBP205.0 million on admission. A week ago, it had announced it plans to raise GBP40.0 million via a placing. On Tuesday, it said about 105.1 million shares ...

(Alliance News) - Valterra Platinum Ltd on Tuesday reported lower production for the first nine months of 2025 as it continued to recover from floods that hit a key mine early this year.

C&C declared an interim dividend of 2.08 cents per share, up 4.0% from 2.00 cents a year prior. It said it still intends to return EUR150 million shareholders via a combination of dividends and share ...

Long Path Partners described itself as "an enduring partner for Idox's next stage", adding: "Operating as a private company, Idox would be well-positioned to invest in product and technology to ...